
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, March 30, 2023.
Inventiva’s 2022 full-year financial results will be published on Wednesday, March 29, 2023
at 4:00 pm (New York), 10:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, onThursday, March 30, 2023,
at8:00 am (New York), 2:00pm (Paris).
The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/jdzcm24d and also available on Inventiva’s onwards in the “Investors” – “Financial results” section.
In order to receive the conference access information necessary to join the conference call, it isrequired toregister in advance using the following link:
https://register.vevent.com/register/BI64f8e310179a49e2a675a18f401f7241.
In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering (dial-in number and access code).
A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.
Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.
Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting an oncology development candidate for its Hippo signaling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva Pascaline Clerc VP of Global External Affairs media@inventivapharma.com +1 240 620 9175 | Brunswick Group Tristan Roquet Montegon / Aude Lepreux Matthieu Benoist Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83 | Westwicke, an ICR Company Patricia L. Bank Investor relations patti.bank@westwicke.com +1 415 513 1284 |
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Report for the first quarter of 202330.5.2023 19:43:43 CEST | Press release
Oslo, 30 May 2023 Highlights in the period Gross production in Q1 2023 decreased 21% compared to Q4 2022.In January 2023, the Company timely paid accrued and due interest on its corporate bond. Early in February 2023, the Company was notified of the formal approval to its acquisition of the 8.34% participating interests in five concessions in Santa Cruz, Argentina where the Company also serves as operator. The Company has worked with the relevant Provincial authorities on the satisfaction of the requirements to restart full activities in the MMO and Cañadón Ramírez fields (Chubut, Argentina) and reopened such fields. For more information, please see enclosed Interoil Exploration and Production ASA's Report for the first quarter of 2023. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. *************************** Please direct any further questions to ir@interoil.no (mailto:ir@interoil.no) About Interoil Intero
Change in management30.5.2023 19:41:51 CEST | Press release
The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023. Anders Fink Vadsholt states:” With the latest progress in our US security class action case described in company announcement of 17 April 2023, and a successful sale and hand over of all activities to Zevra Therapeutics (Previously Kempharm), I see my job as CEO/CFO successfully completed and the time has come for me to look for new challenges. I would like to thank all former colleagues in Orphazyme for years of dedicated work and loyalty”. Chairman Michael Hove states: On behalf of the board, I would like to thank Mr. Vadsholt for his dedicated work especially during the pas
Transfer of Harvia's own shares as rewards under the incentive program30.5.2023 19:35:00 CEST | Press release
Harvia Plc, Stock Exchange Release, May 30, 2023 at 8:35 p.m. EEST The Board of Directors of Harvia Plc has on 3 May 2023 decided on a directed share issue without consideration for the payment of rewards earned under the company’s share-based incentive program. The share payments concern the performance period 2020–2022 of the company’s share-based incentive program launched in 2020. In the share issue, 9,109 own shares held by the company have today been transferred without consideration to the key employees participating in the share-based incentive program in accordance with the program-specific terms and conditions. After the transfer of shares under the incentive program and the shares transferred at the same time as part of the board remuneration, the company holds a total of 9,637 own shares. The decision on the transfer of shares is based on the authorization granted to the Board of Directors by the Annual General Meeting on 20 April 2023. No new shares shall be issued in conn
Transfer of Harvia’s own shares as part of remuneration of the Board30.5.2023 19:30:00 CEST | Press release
Harvia Plc, Stock Exchange Release, 30 May 2023 at 8:30 p.m. EEST Based on the decision of the General Meeting held 20 April 2023, Harvia Oyj has on 30 May 2023 transferred a total of 2,328 own shares possessed by the company to members of the Board of Directors of Harvia Oyj as part of the Board’s remuneration. After the transfer of shares as part of the board remuneration and the shares transferred at the same time under the incentive program, the company holds a total of 9,637 own shares. Based on the decision of the General Meeting of Harvia Oyj, the monthly remuneration of the Board members will be paid in company shares and in cash in such a way that approximately 40 per cent of the total monthly remuneration will be paid in company shares purchased at a price determined in public trading on Nasdaq Helsinki Ltd and approximately 60 per cent will be paid in cash. The company will pay any costs and transfer tax related to the purchase of company shares. In case the remuneration can
Vesting af warranter samt ledende medarbejderes transaktioner30.5.2023 19:18:09 CEST | pressemeddelelse
Selskabet har dags dato modtaget meddelelse om at Direktion og bestyrelse ønsker at exercise ialt 5.983.524 stk. warranter fra tildelingsåret maj 2020 (Selskabsmeddelelse 20/2020). Warrantprogrammet blev tildelt direktion og bestyrelse i maj 2020, og indehaverne af warranterne udnytter nu deres respektive programmer, og herefter udestår ingen aktieoptioner fra tildelingsåret maj 2020. Udnyttelseskursen er ved tildelingen i maj 2020 fastsat til DKK 1,53 pr. aktie af nominelt DKK 0,5, jf. selskabsmeddelelse 20/2020. Selskabet har som led i udnyttelsen af aktieoptionerne afhændet 5.983.524 stk. egne aktier til et samlet beløb på DKK 9.154.791,72, og således foretages der ingen kapitalforhøjelse i forbindelse med udnyttelsen af aktieoptionerne. Selskabets egen aktiebeholdning er efter frasalget reduceret til i alt 0 aktier. I forbindelse med gennemførelsen af ovenstående transaktioner har selskabet modtaget vedhæftede indberetninger fra direktionen og bestyrelsens respektive transaktioner.